Roche's VENTANA MMR RxDx Panel Secures IVDR Approval As Companion Diagnostic Across Five Cancer Types, Six Indications For Keytruda, Imfinzi, Lynparza And Jemperli

ROCHE HOLDINGS AG
ROCHE HOLDINGS AG
ROCHE HOLDINGS AG

ROCHE HOLDINGS AG

RHHBF

0.00

ROCHE HOLDINGS AG

RHHBY

0.00

ROCHE HOLDINGS AG

RHHVF

0.00
  • Used as a predictive biomarker, the first-of-its-kind VENTANA MMR RxDx Panel helps identify cancer patients eligible for treatment with certain precision oncology therapies
  • By evaluating a panel of MMR proteins in tumours, the test provides clinicians with a standardised testing option to determine mismatch repair (MMR) status
  • This IVDR approval expands the companion diagnostic's label to include five cancer types and six indications
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.